Repros Therapeutics Inc. (NASDAQ:RPRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 24, 2017, Jaye Thompson, Ph.D., Senior Vice President of Clinical and Regulatory of Repros Therapeutics Inc. (the “Company”), separated from the Company, effective May 24, 2017. Dr. Thompson is expected to enter into a separation agreement with the Company in the near future that will provide for a severance payment consisting of six and one-half months of salary and the continuation of Company-paid benefits for a six month period, as well as providing for Dr. Thompson to have two years to exercise her vested stock options outstanding as of her retirement. The separation agreement is also expected to provide that Dr. Thompson is bound by certain restrictive covenants, including non-compete and non-solicitation provisions, and to contain a release by Dr. Thompson of all claims against the Company, subject to certain enumerated exceptions.

About Repros Therapeutics Inc. (NASDAQ:RPRX)

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Repros Therapeutics Inc. (NASDAQ:RPRX) Recent Trading Information

Repros Therapeutics Inc. (NASDAQ:RPRX) closed its last trading session down -0.020 at 0.470 with 302,279 shares trading hands.